Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral T cell lymphoma (PTCL) Meeting Abstract
| Authors: | Horwitz, S. M.; Hamlin, P. A.; Feldman, T.; Hess, B. T.; Mato, A. R.; Munoz, J.; Patel, M. R.; Ye, J. C.; Steele, A.; Pandey, A.; Birrell, M.; Leeds, J.; Coffey, G.; Curnutte, J. T. |
| Abstract Title: | Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral T cell lymphoma (PTCL) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Language: | English |
| ACCESSION: | WOS:000442916006346 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.e19532 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: e19532 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
